Moderna, Inc. settles LNP patent dispute for $950M, securing royalty-free tech access and legal clarity; click for what it ...

Moderna Inc.’s settlement to end a lawsuit over technology used in its Covid-19 vaccine caps its potential exposure at $2.25 ...

Moderna will pay up to $2.25B to settle a patent lawsuit over lipid nanoparticle technology used in its COVID-19 vaccine.

Moderna Inc. (NASDAQ:MRNA) is one of the 10 Stocks Dominating Today’s Market Action. Moderna snapped a two-day losing streak on Wednesday, jumping 15.99 percent to finish at $57.80 apiece after ...

Moderna to pay $950 million with no future royalties to resolve all global litigation; corresponding charge expected in ...

Moderna Inc MRNA shares are trading higher on Monday. Piper Sandler boosted its price target on the stock to $69 from $63 ...

Stéphane Bancel, chief executive of Cambridge-based Moderna, said in a statement that resolving the case “removes uncertainty." ...

TD Cowen 46th Annual Health Care Conference March 3, 2026 1:50 PM ESTCompany ParticipantsJames Mock - Chief Financial ...

Moderna (MRNA) stock jumped 8.7% after announcing a $950M patent settlement with Arbutus and Genevant, the largest pharma patent deal ever recorded.

This prompts a reassessment of the stock’s value to determine if this represents a genuine opportunity or a potential trap.

Moderna has entered into a settlement agreement resolving all worldwide Arbutus Biopharma Corporation/Genevant Sciences GmbH ...

BioNTech SE BNTX has filed a patent infringement lawsuit against Moderna Inc. MRNA, alleging that Moderna's next-generation COVID-19 vaccine, mNEXSPIKE, relies on proprietary technology developed and ...